( Editorial: --> 8642 )
ZAGREB, Sept 7 (Hina) - Croatia's pharmaceutical giant Pliva on
Monday signed a licensing agreement with Receptron, Inc., a
California-based biotechnological company.
The agreement gives Pliva exclusive rights to the development of
medicines which act similarly to endogenous trombopoetine (TPO),
but have additional advantages as well.
In line with the agreement, Pliva will assist Receptron in
research, pay out exclusive rights and royalties from future
sales.
TPO is a growth agent which stimulates the production of blood
vessels.
It should also replace transfusions which are expensive and high-
risk due to possibilities of HIV and hepatitis infections.
It is expected the TPO product's market potential will be in excess
of US$500 million.
(hina) ha jn/sp
071640 MET sep 98
SP skijaško trčanje: Treće zlato za Klaeba u Trondheimu, Skender 96.
Gospodarstvo - ukratko do 14,30 sati
Kovesi: Vlada mora promijeniti zakon, Turudić ne bi trebao odlučivati o nadležnosti
Izložba "Eros u kamenu" otvara se u Laubi – Kući za ljude i umjetnost
UN: Djeca od godinu dana među žrtvama silovanja u građanskom ratu u Sudanu
Minamino u Monacu do ljeta 2027.
Tomašević najavio u idućem mandatu gradnju 1000 stanova za priuštivo stanovanje
Nezaposlenost u eurozoni stabilna u siječnju; u Hrvatskoj blago smanjena
Bayern će pod krovom Allianz Arene izložiti Beckenbauerov dres s bojem 5
Brnabić optužila oporbu za incidente u Skupštini, ozlijeđene tri zastupnice